BioCentury on BioBusiness,
Europe's emigrant money
Monday, July 10, 2000
While European biotech companies are raising a third to two-thirds
as much as their U.S. counterparts in their venture, IPO and follow-on financings,
a small river of European money is flowing across the pond into U.S.-based life
science companies. According to European buysiders, there are two fundamental
reasons for money leaving the Continent: a shortage of investment opportunities
in Europe and better valuations in the U.S.
European investors provided $397.2 million (12 percent) of
the $3.3 billion accounted for by 25 marquee U.S. financings this year, represented
by the top 10 each of IPOs and venture financings, and five of the top 10 follow-ons
for which European allocation was made available. By comparison, European companies
in total raised only 3.5 times that amount ($1.39 billion) in IPOs, follow-ons
and venture rounds through June 30.
European money is playing the most significant role (on a percentage
basis) in U.S. venture rounds and IPOs. Of the $478.6 million raised in the
10 largest U.S. private rounds, Europeans provided $80.1 million (17 percent).
And European investors purchased $227.2 million (14 percent) of the $1.6 billion
raised in the top 10 U.S. IPOs. By contrast, only 7 percent of the paper from
5 of the top 10 U.S. follow-ons - $90 million out of $1.3 billion - was sold
With their financial lifeblood being exported to the U.S.,
the phenomenon may be particularly frustrating for European life science executives.
While the amount of money raised by global life science companies has been increasing
steadily, Europe's take has fallen from 28 percent of the total money raised
for the industry in 1996 to a mere 8 percent of the industry's take through
June 30 of this year.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]